Equasens (EQS.PA) Stock Price

Equasens Price

Euronext·CLOSED
34.00EUR+0.05 (+0.15 %)
Market closed

Over the last 19 years Equasens grew revenue by 6.8% annually, reaching 236.52 M EUR. Earnings per share have grown at 9.2% per year over the last 19 years. For Equasens, the net margin of 16.6% is down versus 20.3% a few years ago. At today's price the dividend yield works out to roughly 3.68%. The payout ratio is around 49% of earnings. The dividend has grown at 0.7% per year over the past 19 years. The consensus 12-month price target for Equasens is 53.04 EUR, about 56.0% above where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 4% above its 52-week low.

Equasens stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Equasens over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Equasens stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Equasens's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Equasens Stock Price History
DateEquasens Price
8/7/202634.00 EUR
8/6/202633.95 EUR
8/5/202633.50 EUR
8/4/202632.75 EUR
7/31/202632.75 EUR
7/30/202634.45 EUR
7/29/202634.40 EUR
7/28/202633.80 EUR
7/27/202634.10 EUR
7/24/202634.10 EUR
7/23/202633.15 EUR
7/22/202633.45 EUR
7/21/202633.50 EUR
7/20/202633.35 EUR
7/17/202633.50 EUR
7/16/202633.80 EUR
7/15/202633.70 EUR
7/14/202633.75 EUR
7/13/202634.20 EUR
7/10/202633.35 EUR
7/9/202632.75 EUR
7/8/202632.80 EUR
7/7/202633.25 EUR
7/6/202634.00 EUR
7/3/202634.80 EUR
7/2/202634.75 EUR
7/1/202634.10 EUR
6/30/202634.50 EUR
6/29/202634.95 EUR
6/26/202635.20 EUR
6/25/202635.05 EUR
6/24/202635.20 EUR
6/23/202634.80 EUR
6/22/202634.80 EUR
6/19/202635.55 EUR
6/18/202636.15 EUR
6/17/202636.80 EUR
6/16/202637.00 EUR
6/15/202638.40 EUR
6/12/202638.00 EUR
6/11/202638.75 EUR
6/10/202639.00 EUR
6/9/202638.90 EUR
6/8/202639.15 EUR
6/5/202639.10 EUR
6/4/202638.30 EUR
6/3/202638.15 EUR
6/2/202638.90 EUR
6/1/202639.25 EUR
5/29/202639.10 EUR
5/28/202638.50 EUR
5/27/202638.30 EUR
5/26/202638.35 EUR
5/25/202638.20 EUR
5/22/202637.60 EUR
5/21/202637.45 EUR
5/20/202637.20 EUR
5/19/202637.05 EUR
5/18/202637.25 EUR
5/15/202637.00 EUR
5/14/202636.90 EUR
5/13/202636.35 EUR
5/12/202636.70 EUR
5/11/202636.45 EUR
5/8/202635.95 EUR
5/7/202636.90 EUR
5/6/202636.45 EUR
5/5/202636.80 EUR
5/4/202637.30 EUR
4/30/202637.50 EUR
4/29/202639.20 EUR
4/28/202639.85 EUR
4/27/202639.80 EUR
4/24/202639.55 EUR
4/23/202640.50 EUR
4/22/202640.95 EUR
4/21/202642.45 EUR
4/20/202641.75 EUR
4/17/202641.65 EUR
4/16/202641.00 EUR
4/15/202641.05 EUR
4/14/202640.05 EUR
4/13/202640.10 EUR
4/10/202639.50 EUR
4/9/202638.80 EUR
4/8/202639.65 EUR
4/7/202639.20 EUR
4/2/202638.28 EUR
3/27/202634.30 EUR
3/26/202634.00 EUR
3/25/202633.90 EUR
3/24/202633.90 EUR
3/23/202634.85 EUR
3/20/202634.95 EUR
3/19/202634.55 EUR
3/18/202635.00 EUR
3/17/202634.85 EUR
3/16/202635.60 EUR
3/13/202635.30 EUR
3/12/202636.10 EUR
3/11/202636.20 EUR
3/10/202636.85 EUR
3/9/202637.70 EUR
3/6/202636.65 EUR
3/5/202635.45 EUR
3/4/202635.20 EUR
3/3/202634.05 EUR
3/2/202634.75 EUR
2/27/202635.35 EUR
2/26/202635.80 EUR
2/25/202634.20 EUR
2/24/202634.10 EUR
2/23/202634.45 EUR
2/20/202634.40 EUR
2/19/202634.30 EUR
2/18/202635.25 EUR
2/17/202635.35 EUR
2/16/202635.90 EUR
2/13/202636.55 EUR
2/12/202636.50 EUR
2/11/202637.00 EUR
2/10/202638.75 EUR
2/9/202638.25 EUR
2/6/202638.60 EUR
2/5/202639.80 EUR
2/4/202639.80 EUR
2/3/202639.95 EUR
2/2/202639.60 EUR
1/30/202639.60 EUR
1/29/202639.70 EUR
1/28/202640.00 EUR
1/27/202640.25 EUR
1/26/202640.25 EUR
1/23/202640.70 EUR
1/22/202640.70 EUR
1/21/202640.00 EUR
1/20/202640.65 EUR
1/19/202640.50 EUR
1/16/202640.85 EUR
1/15/202641.90 EUR
1/14/202641.80 EUR
1/13/202642.15 EUR
1/12/202643.15 EUR
1/9/202644.00 EUR
1/8/202643.85 EUR
1/7/202643.50 EUR
1/6/202644.00 EUR
1/5/202641.90 EUR
1/2/202644.85 EUR
12/31/202545.00 EUR
12/30/202544.95 EUR
12/29/202544.85 EUR
12/24/202544.45 EUR
12/23/202543.60 EUR
12/22/202543.90 EUR
12/19/202543.90 EUR
12/18/202543.75 EUR
12/17/202544.25 EUR
12/16/202544.25 EUR
12/15/202544.25 EUR
12/12/202543.50 EUR
12/11/202543.15 EUR
12/10/202542.45 EUR
12/9/202542.60 EUR
12/8/202543.10 EUR
12/5/202543.20 EUR
12/4/202542.95 EUR
12/3/202541.40 EUR
12/2/202541.75 EUR
12/1/202541.90 EUR
11/28/202542.95 EUR
11/27/202542.90 EUR
11/26/202542.00 EUR
11/25/202541.90 EUR
11/24/202542.05 EUR
11/21/202541.25 EUR
11/20/202540.95 EUR
11/19/202541.15 EUR
11/18/202541.15 EUR
11/17/202541.95 EUR
11/14/202541.75 EUR
11/13/202541.65 EUR
11/12/202542.00 EUR
11/11/202540.95 EUR
11/10/202541.05 EUR
11/7/202540.25 EUR
11/6/202540.25 EUR
11/5/202536.85 EUR
11/4/202536.65 EUR
11/3/202537.50 EUR
10/31/202537.95 EUR
10/30/202537.75 EUR
10/29/202538.00 EUR
10/28/202538.60 EUR
10/27/202538.75 EUR
10/24/202540.65 EUR
10/23/202540.70 EUR
10/22/202540.40 EUR
10/21/202539.90 EUR
10/20/202540.50 EUR
10/17/202540.70 EUR
10/16/202541.35 EUR
10/15/202539.00 EUR
10/14/202538.65 EUR
10/13/202539.80 EUR
10/10/202539.05 EUR
10/9/202540.25 EUR
10/8/202540.90 EUR
10/7/202540.40 EUR
10/6/202540.35 EUR
10/3/202540.55 EUR
10/2/202540.00 EUR
10/1/202539.85 EUR
9/30/202539.70 EUR
9/29/202540.70 EUR
9/26/202544.50 EUR
9/25/202545.35 EUR
9/24/202545.85 EUR
9/23/202546.00 EUR
9/22/202546.20 EUR
9/19/202545.50 EUR
9/18/202545.40 EUR
9/17/202544.25 EUR
9/16/202543.75 EUR
9/15/202544.85 EUR
9/12/202543.45 EUR
9/11/202543.70 EUR
9/10/202545.30 EUR
9/9/202545.30 EUR
9/8/202544.60 EUR
9/5/202545.00 EUR
9/4/202543.90 EUR
9/3/202543.70 EUR
9/2/202543.80 EUR
9/1/202545.70 EUR
8/29/202545.75 EUR
8/28/202546.00 EUR
8/27/202546.35 EUR
8/26/202547.00 EUR
8/25/202548.80 EUR
8/22/202549.25 EUR
8/21/202548.05 EUR
8/20/202548.05 EUR
8/19/202549.55 EUR
8/18/202549.70 EUR
8/15/202549.70 EUR
8/14/202550.00 EUR
8/13/202550.00 EUR
8/12/202550.30 EUR
Access this data via the Eulerpool API
Get Free API Key

Equasens Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
214.08 M EUR
56.23 M EUR
46.25 M EUR
Jan 1, 2023
219.79 M EUR
55.41 M EUR
47.05 M EUR
Jan 1, 2024
216.75 M EUR
44.64 M EUR
36.23 M EUR
Jan 1, 2025
236.52 M EUR
47.73 M EUR
39.33 M EUR
Jan 1, 2026 (e)
253.45 M EUR
64.51 M EUR
42.79 M EUR
Jan 1, 2027 (e)
269.90 M EUR
68.49 M EUR
49.92 M EUR
Jan 1, 2028 (e)
293.14 M EUR
72.43 M EUR
54.91 M EUR
Jan 1, 2029 (e)
307.90 M EUR
76.08 M EUR
0.00 EUR

Equasens Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:40 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
114.00113.00128.00129.00148.00158.00171.00193.00214.00219.00216.00236.00253.00269.00293.00307.00
0.88-0.8813.270.7814.736.768.2312.8710.882.34-1.379.267.206.328.924.78
23.6829.2028.9128.6828.3827.8528.6527.4627.5725.5721.7620.7620.7620.7620.7620.76
27.0033.0037.0037.0042.0044.0049.0053.0059.0056.0047.0049.0052.5355.8560.8363.74
25.0027.0031.0034.0038.0040.0046.0050.0056.0055.0044.0047.0064.0068.0072.0076.00
21.9323.8924.2226.3625.6825.3226.9025.9126.1725.1120.3719.9225.3025.2824.5724.76
17.0018.0020.0023.0025.0028.0030.0039.0046.0047.0036.0039.0042.0049.0054.00–
13.335.8811.1115.008.7012.007.1430.0017.952.17-23.408.337.6916.6710.20–
2.502.900.600.650.750.850.900.951.051.151.251.251.331.431.52–
19.0516.00-79.318.3315.3813.335.885.5610.539.528.70–6.407.526.29–
15.1915.1715.1715.1715.1715.0315.0715.2915.3015.1715.0315.2915.2915.2915.2915.29
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Equasens generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Equasens retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Equasens's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Equasens has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Equasens's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Equasens stock margins

The Equasens margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Equasens. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Equasens.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
27.87 %
26.04 %
20.26 %
Jan 1, 2022
27.56 %
26.26 %
21.60 %
Jan 1, 2023
25.78 %
25.21 %
21.41 %
Jan 1, 2024
21.75 %
20.59 %
16.72 %
Jan 1, 2025
21.03 %
20.18 %
16.63 %
Jan 1, 2026 (e)
21.03 %
25.45 %
16.88 %
Jan 1, 2027 (e)
21.03 %
25.38 %
18.50 %
Jan 1, 2028 (e)
21.03 %
24.71 %
18.73 %

Equasens Stock Revenue, EBIT, Earnings per Share

The Equasens earnings per share therefore indicates how much revenue Equasens has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
12.63 EUR
3.29 EUR
2.56 EUR
Jan 1, 2022
13.99 EUR
3.67 EUR
3.02 EUR
Jan 1, 2023
14.48 EUR
3.65 EUR
3.10 EUR
Jan 1, 2024
14.42 EUR
2.97 EUR
2.41 EUR
Jan 1, 2025
15.47 EUR
3.12 EUR
2.57 EUR
Jan 1, 2026 (e)
16.70 EUR
4.22 EUR
2.82 EUR
Jan 1, 2027 (e)
17.79 EUR
4.48 EUR
3.29 EUR
Jan 1, 2028 (e)
19.32 EUR
4.74 EUR
3.62 EUR

Equasens business model & stock analysis

Pharmagest Interactive SA is a leading provider of digital solutions for pharmacies and healthcare providers. The company was founded in France in 1986 and is headquartered in Villers-lès-Nancy. The company offers a wide range of software solutions for healthcare providers and pharmacies. Its main business areas include pharmacy management systems, healthcare management solutions, and telemedicine solutions. Pharmagest Interactive SA's pharmacy management systems include software solutions for inventory management, prescription management, and billing. The company also provides e-learning courses and training for pharmacies. Its healthcare management solutions focus on patient data management, with features such as patient records, appointment scheduling, and prescription management. These solutions are used by healthcare providers to optimize patient data management and improve patient care. Pharmagest Interactive SA also offers telemedicine solutions, including remote visit applications, online consultations, and teleconsultations. These solutions are particularly useful for patients in rural areas or with limited mobility. The company's products and services include Crossway, a pharmacy management software; LGPI, a patient management software for hospitals and healthcare providers; Noviatek, a digital prescription management system; and Monolog, a cloud-based platform for telemedicine services. In summary, Pharmagest Interactive SA provides a variety of digital solutions for pharmacies and healthcare providers, focusing on optimizing patient data management, inventory management, and billing. The company is also a pioneer in telemedicine solutions.

Equasens SWOT Analysis

Strengths

Pharmagest Interactive SA has several strengths that contribute to its success:

  • Strong brand reputation in the pharmaceutical industry
  • Wide range of innovative software solutions for pharmacies
  • Established customer base with long-term contracts
  • Strong financial position with steady revenue growth
  • Experienced and knowledgeable management team

Weaknesses

However, Pharmagest Interactive SA also faces some weaknesses that it needs to address:

  • Reliance on a single industry for revenue generation
  • Limited international presence and dependence on the French market
  • Competitive market with new entrants and potential substitutes
  • Need for continuous investment in research and development
  • Dependency on third-party vendors and technology partners

Opportunities

There are several opportunities that Pharmagest Interactive SA can capitalize on:

  • Expansion into new markets and regions
  • Growing demand for digital solutions in the healthcare industry
  • Partnerships with pharmaceutical manufacturers for product integration
  • Development of mobile applications and telehealth solutions
  • Acquisition of smaller competitors to increase market share

Threats

Pharmagest Interactive SA should also be aware of the following threats:

  • Rapidly changing technology landscape and evolving customer needs
  • Increased regulations and compliance requirements in the healthcare sector
  • Emergence of new disruptive technologies or business models
  • Potential loss of key customers to competitors
  • Economic downturn or financial instability impacting customer spending

Equasens Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Equasens historical P/E ratio, EBIT multiple, and P/S ratio

Equasens annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Equasens shares outstanding

The number of shares of Equasens was 15.29 M in 2025. This indicates how many shares Equasens is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
15.29 M Stocks
Jan 1, 2022
15.30 M Stocks
Jan 1, 2023
15.17 M Stocks
Jan 1, 2024
15.03 M Stocks
Jan 1, 2025
15.29 M Stocks
Jan 1, 2026 (e)
15.29 M Stocks
Jan 1, 2027 (e)
15.29 M Stocks
Jan 1, 2028 (e)
15.29 M Stocks

Equasens stock splits

In Equasens's history, there have been no stock splits.

Equasens Dividend History

23 years of dividend payments

YearAnnual DividendYoY ChangePayments
20251.25EUR 0.0%1×
Jul 2, 20251.25EUR 0.0%1/1
20241.25EUR↑ 8.7%1×
20231.15EUR↑ 9.5%1×
20221.05EUR↑ 10.5%1×
20210.95EUR↑ 5.6%1×
20200.90EUR↑ 5.9%1×
20190.85EUR↑ 13.3%1×
20180.75EUR↑ 15.4%1×
20170.65EUR↑ 8.3%1×
20160.60EUR↓ 79.3%1×

Equasens dividend history and estimates

In 2025, Equasens paid a dividend amounting to 1.25 EUR. Dividend means that Equasens distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.95 EUR
0.00 EUR
Jan 1, 2022
1.05 EUR
0.00 EUR
Jan 1, 2023
1.15 EUR
0.00 EUR
Jan 1, 2024
1.25 EUR
0.00 EUR
Jan 1, 2025
1.25 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
1.33 EUR
Jan 1, 2027 (e)
0.00 EUR
1.43 EUR
Jan 1, 2028 (e)
0.00 EUR
1.52 EUR

Equasens dividend payout ratio

In 2025, Equasens had a payout ratio of 48.59%. The payout ratio indicates the percentage of the company's profits that Equasens distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
37.13 %
Jan 1, 2022
34.74 %
Jan 1, 2023
37.09 %
Jan 1, 2024
51.86 %
Jan 1, 2025
48.59 %
Jan 1, 2026 (e)
47.34 %
Jan 1, 2027 (e)
43.33 %
Jan 1, 2028 (e)
42.07 %

Current Equasens forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
83.33 % (5)
Hold
16.67 % (1)
Sell
0.00 % (0)
12M Price Target
53.04
Last Price
33.95
Currency
EUR
12M Return Potential
56.23 %
LTM Return
0 %

Equasens shareholder structure

% Name
66.64023%
Groupe Welcoop
Groupe Welcoop
1.15507%
DNCA Investments
DNCA Investments
1.08375%
Danske Bank Asset Management
Danske Bank Asset Management
1.00886%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.92928%
Amundi Asset Management, SAS
Amundi Asset Management, SAS
0.85535%
Montanaro Asset Management Limited
Montanaro Asset Management Limited

Equasens Beneficial Ownership Filings (SEC 13D/G)

Free Float
32.5%
Float Shares
-
Shares Outstanding
-

Equasens Executives and Management Board

13 members · avg. age 59 · 46 % women

DS

Mr. Denis Supplisson (56)

Chief Executive Officer, Member of the Management Board, Director

227,237.00 EUR

Management

GR

Mr. Gregoire de Rotalier (55)

Deputy Chief Executive Officer, Director · since 2020

–

Board of Directors

TC

Mr. Thierry Chapusot (66)

Chairman of the Board · since 2010

717,424.00 EUR
AP

Ms. Anne Philipona-hintzy (53)

Independent Director

25,770.00 EUR
DP

Mr. Dominique Pautrat (60)

Director · since 2000

24,000.00 EUR
FJ

Mr. Francois Jacquel (66)

Director

7,770.00 EUR
DA

Mr. Daniel Antoine (73)

Director

7,062.00 EUR
SM

Mrs. Sophie Mayeux (68)

Independent Director

6,531.00 EUR

Frequently asked questions about Equasens

Pharmagest Interactive SA operates on a business model that combines both software publishing and IT services. As a leading provider in the healthcare sector, the company specializes in the development and integration of computerized management solutions for pharmacies, hospitals, and healthcare professionals. Pharmagest Interactive SA offers a wide range of innovative products and services, including pharmacy information systems, medication dispensing robots, patient monitoring tools, and digital solutions for telemedicine. By facilitating efficient and secure workflows, their solutions contribute to improving patient care and optimizing pharmaceutical processes. Pharmagest Interactive SA continues to innovate and adapt to the evolving needs of the healthcare industry, positioning itself as a reliable partner for digital transformation in the sector.

Pharmagest Interactive SA primarily operates in the healthcare industry.

The main competitors of Pharmagest Interactive SA in the market include leading healthcare technology companies such as Cerner Corporation, Allscripts Healthcare Solutions, and Epic Systems Corporation. These companies also provide innovative software solutions for healthcare management, electronic health records, and pharmacy point-of-sale systems. Pharmagest Interactive SA competes by offering comprehensive and customizable solutions specifically designed for pharmacies, hospitals, and healthcare institutions. With its unparalleled expertise and dedication, Pharmagest Interactive SA continues to stand out in the market, providing advanced technology solutions to enhance pharmacy operations and improve patient care.

Pharmagest Interactive SA is a leading company in the healthcare sector. Founded in 1980, the company has a rich history of providing innovative solutions and services to pharmacies and healthcare professionals. Pharmagest Interactive SA specializes in developing software for medication management, patient care, and pharmacy automation. With a strong commitment to leveraging technology in the healthcare industry, Pharmagest Interactive SA has grown to become a trusted partner for pharmacies across Europe. The company's dedication to delivering high-quality solutions has earned them a strong reputation and a competitive edge in the market. Pharmagest Interactive SA continues to evolve and adapt to the changing needs of the healthcare sector, ensuring enhanced patient outcomes and operational efficiency for its clients.

Pharmagest Interactive SA has achieved several significant milestones throughout its history. The company has successfully forged strategic partnerships with leading healthcare organizations, enhancing its market position and expanding its reach. Pharmagest has consistently demonstrated its commitment to innovation by developing cutting-edge technological solutions tailored for the healthcare sector. Furthermore, the company has achieved remarkable growth, both organically and through acquisitions, establishing itself as a key player in the pharmacy management software industry. Pharmagest's dedication to providing comprehensive and integrated services has been widely recognized, earning the company a strong reputation among investors and healthcare professionals alike.

Pharmagest Interactive SA is primarily present in France.

Pharmagest Interactive SA represents strong values and a dedicated corporate philosophy. The company is committed to excellence in the field of healthcare and technology solutions. Pharmagest Interactive SA places great importance on innovation, ensuring that they stay at the forefront of the industry. They prioritize customer satisfaction, aiming to provide exceptional products and services. With a focus on quality, reliability, and creating sustainable partnerships, Pharmagest Interactive SA aims to contribute to the advancement of healthcare worldwide. Their unwavering commitment to these values has made them a trusted name in the industry, thus solidifying their position as a leader in healthcare technology solutions.

Analysts currently set an average price target of 54.06 EUR for the Equasens stock (median: 53.04 EUR), implying +59.2 % versus the latest price. The consensus is based on 6 analyst ratings.

Equasens Analyst Price Targets 2026

6 analysts currently rate the Equasens stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Equasens to generate revenue of 253.45 M EUR and earnings per share of 2.80 EUR.

Equasens Analyst Price Targets 2026

The Equasens share (EQS.PA) is listed on 6 stock exchanges, including: Frankfurt (PHF.F), München (PHF.MU), London (0R9T.L), London (0R9T.L), Paris (EQS.PA).

Pharmagest Interactive SA is a leading provider of IT solutions for the healthcare industry. The company is headquartered in France and operates in Europe, North America, and the Middle East. Pharmagest Interactive SA has five business areas that offer various IT solutions for pharmacies, hospitals, senior facilities, and retail. The pharmacy division offers specialized software solutions such as WinPharm and LGPI, which allow pharmacies to optimize their management and simplify their business processes. The solutions include inventory management, billing and accounting, and customer communication. Additionally, Pharmagest Interactive SA also offers an online pharmacy called easypharmacie, through which customers can order their medications online and have them delivered directly to their homes. In the hospital division, the company offers solutions for electronic medical records, patient management, mobile caregiving, and image analysis. These solutions allow hospitals to streamline their processes, increase efficiency, and improve patient satisfaction. The senior facility division offers IT solutions to enhance the management of nursing homes and senior residences. The solutions include resident management, staff and resource planning, as well as billing and accounting. These solutions can help senior facilities optimize their operations and increase the quality of care. In the retail division, Pharmagest Interactive SA offers solutions tailored specifically to retailers. The solutions include customer management, inventory management, point-of-sale systems, as well as marketing and analysis tools. With these solutions, retailers can increase sales, improve customer loyalty, and optimize their business processes. The telemedicine division offers a platform called "CareSpeak" that aims to improve communication between patients and healthcare facilities. With this solution, medical professionals can communicate quickly and effectively with patients without the need for physical contact. Pharmagest Interactive SA specializes in meeting the needs of the healthcare industry and offers IT solutions tailored to pharmacies, hospitals, senior facilities, retailers, and telemedicine providers. These comprehensive IT solutions help customers optimize their business processes, minimize risks, and improve the quality of healthcare.

The expected revenue of Equasens is 253.45 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Equasens is 42.79 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Equasens is currently 12.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Equasens stock.

The price-to-sales ratio (P/S) of Equasens is currently 2.05. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Equasens stock.

The Eulerpool Quality Score for Equasens is 6/10.

The ISIN of Equasens is FR0012882389. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Equasens is A14XZH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Equasens is EQS.PA. The ticker symbol is used to trade Equasens shares on the stock exchange.

Over the past 12 months, Equasens paid a dividend of 1.25 EUR . This corresponds to a dividend yield of about 3.68 %. For the coming 12 months, Equasens is expected to pay a dividend of 1.43 EUR.

The current dividend yield of Equasens is 3.68 %.

Equasens pays a dividend, distributed in the months of , , , .

Equasens paid dividends every year for the past 23 years.

For the upcoming 12 months, dividends amounting to 1.43 EUR are expected. This corresponds to a dividend yield of 4.19 %.

Equasens is assigned to the 'Health' sector.

To receive the latest dividend of Equasens from amounting to 1.25 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Equasens distributed 1.25 EUR as dividends.

The dividends of Equasens are distributed in EUR.

All fundamentals and in-depth analysis of Equasens

Our stock analysis for Equasens stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Equasens. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Equasens Stock
Equasens Revenue→
Equasens Stock
Equasens Net Income→
Equasens Stock
Equasens P/E→
Equasens Stock
Equasens P/S→
Equasens Stock
Equasens EBIT→
Equasens Stock
Equasens Dividend→
Equasens Stock
Equasens Directors Dealings→
Equasens Stock
Equasens Stocks→
Equasens Stock
Equasens Market capitalization→
Equasens Stock
Equasens Debt→
Equasens Stock
Equasens Liabilities→
Equasens Stock
Equasens Equity→
Equasens Stock
Equasens AAQS→
Equasens Stock
Equasens Employees→
Equasens Stock
Equasens ROE→
Equasens Stock
Equasens ROA→
Equasens Stock
Equasens ROCE→
Equasens Stock
Equasens News→
Equasens Stock
Equasens Analyst Price Targets→

Health Stocks

EquilliumEpsilon HealthcareER Urgent Care HoldingsEPS Bio TechnologyErascaEpisurf MedicalErech Finance CahalachaEpigenomicsEris LifesciencesEone Diagnomics Genome Center CoErnexa TherapeuticsEom Pharmaceutical HoldingsAll Stocks A–Z →